Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the ...

Enrollment completed in the PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in ...

Detailed price information for Sionna Therapeutics Inc (SION-Q) from The Globe and Mail including charting and trades.

Vertex Pharmaceuticals dominates the market for cystic fibrosis drugs, but Sionna Therapeutics contends the pharma company’s products still have efficacy and safety limitations. Sionna has mapped out ...

Additionally, Raymond James raised its price target for Sionna Therapeutics to $53, citing the potential of upcoming proof-of-concept readouts for NBD1 stabilizers SION-719 and SION-451, expected ...

WALTHAM, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for ...

Sionna Therapeutics, Inc. has announced the presentation of promising preclinical data at the 48th European Cystic Fibrosis Conference in Milan, showing that its nucleotide-binding domain 1 (NBD1) ...

What Sionna Therapeutics Stock Data Suggests Right Now Sionna Therapeutics (SION) has drawn investor attention after a very large 1 year total return of 216.26%, alongside mixed shorter term moves ...

* 1-year price change calculated using Dec. 24, 2025 as the reference date. Sionna Therapeutics is a clinical-stage biotechnology company focused on advancing innovative treatments for cystic fibrosis ...

Cystic-fibrosis-focused Sionna Therapeutics is joining the Nasdaq this morning with an upsized public offering, while obesity biotech Aardvark Therapeutics unveiled plans for a nine-figure IPO of its ...